Previous 10 | Next 10 |
3 Penny Stocks to Add to Your Watchlist This Month With another day of trading penny stocks over, there is a lot to be excited about. Over the past week, we have seen some major stock market movements. While this can lead to large losses, it can also lead to very sizable gains. To under...
VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, will present at two upcoming conf...
VistaGen will present at upcoming William Blair 42 nd Annual Growth Stock Conference and Jefferies Global Healthcare Conference VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to tra...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ...
VistaGen Therapeutics (NASDAQ:VTGN) on Thursday said the U.S. Food and Drug Administration (FDA) agreed that the company's nasal spray PH94B for the acute treatment of social anxiety disorder (SAD) did not show any abuse potential. The FDA agreed that data from nonclinical and clinical studie...
VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, has announced its new chief legal...
VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, will be presenting its research a...
Research presented at the Annual Meeting of the Society of Biological Psychiatry and of the American Society of Clinical Psychopharmacology highlight fundamentally differentiated mechanism of action for PH94B These preclinical data demonstrate that intranasal radiolabelled...
VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou. Bayer announced China approval of Vitrakvi™ (larotrectinib), a precision medicine for adult and pediatric patients who have advanced solid tumors that harbor a Ne...
VistaGen Therapeutics (NASDAQ:VTGN) and AffaMed Therapeutics said they have completed regulatory preparations to begin a phase 3 trial of VistaGen’s nasal spray PH94B (AM005) for the acute treatment of anxiety in adults with social anxiety disorder (SAD), in the U.S. and China. Th...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...